Reuters logo
BRIEF-FDA approves roll-over combination study of BriaVax with pembrolizumab
October 30, 2017 / 12:53 PM / 24 days ago

BRIEF-FDA approves roll-over combination study of BriaVax with pembrolizumab

Oct 30 (Reuters) - Briacell Therapeutics Corp

* FDA approves the roll-over combination study with checkpoint inhibitor immunotherapies to allow continued access to BriaVax in patients with advanced breast cancer

* Briacell Therapeutics - ‍FDA approved roll-over combination study of BriaVax with pembrolizumab or ipilimumab

* Briacell- ‍FDA approved roll-over combination study for patients previously treated with BriaVax from Phase I/IIa clinical trial in advanced breast cancer​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below